Genital Diseases, Female  >>  Sylvant (siltuximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sylvant (siltuximab) / Jazz
NCT00841191 / 2008-005180-33: A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

Completed
1/2
84
US, Europe
CNTO 328; Anti-interleukin-6 monoclonal antibody, Siltuximab, Siltoximab
Centocor, Inc.
Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms
04/11
04/11

Download Options